Synopsis
Synopsis
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. H 168 68
2. H 168-68
3. H 16868
4. Magnesium, Omeprazole
5. Omeprazole
6. Omeprazole Magnesium
7. Omeprazole Sodium
8. Prilosec
9. Sodium, Omeprazole
1. Omeprazole Sodium
2. Losec Sodium
3. H 168/68 Sodium
4. 95510-70-6
5. Omeprazole Sodium [usan]
6. 161796-78-7
7. Omeprazole (as Sodium)
8. Kv03yz6qlw
9. 95510-70-6 (sodium)
10. Andra
11. Omeprazole Sodium (usan)
12. 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, Sodium Salt
13. 1h-benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
14. (s)-omeprazole Sodium
15. Esomeprazole Sodium Salt
16. Sompraz
17. Sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
18. Unii-kv03yz6qlw
19. Losec Sodium (tn)
20. Esomeprazole Sodium (nexium)
21. Omeprazole Sodium [jan]
22. Chembl2105294
23. H-168/68 Sodium
24. Chebi:31934
25. Omeprazole Sodium [mart.]
26. Hms3651e16
27. Omeprazole Sodium [who-dd]
28. Bcp23377
29. Esomeprazole Sodium (nexium I.v.)
30. Ac-403
31. S5658
32. Akos024255604
33. Bcp9000660
34. Omeprazole Sodium [ep Monograph]
35. Bcp0726000228
36. Sw219428-1
37. D01207
38. Ab01274809-01
39. Q27282459
40. Sodium 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-3ah-benzimidazole
1. Omeprazole Sodium Hydrate
| Molecular Weight | 367.4 g/mol |
|---|---|
| Molecular Formula | C17H18N3NaO3S |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 367.09665690 g/mol |
| Monoisotopic Mass | 367.09665690 g/mol |
| Topological Polar Surface Area | 81.5 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 459 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Esomeprazole sodium |
| Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
| Active Ingredient | Esomeprazole sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 20mg base/vial; eq 40mg base/vial |
| Market Status | Prescription |
| Company | Sun Pharma Global |
| 2 of 4 | |
|---|---|
| Drug Name | Nexium |
| PubMed Health | Esomeprazole |
| Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
| Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
| Active Ingredient | Esomeprazole magnesium |
| Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
| Route | Oral |
| Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
| Market Status | Prescription |
| Company | Astrazeneca |
| 3 of 4 | |
|---|---|
| Drug Name | Esomeprazole sodium |
| Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
| Active Ingredient | Esomeprazole sodium |
| Dosage Form | Injectable |
| Route | Intravenous |
| Strength | eq 20mg base/vial; eq 40mg base/vial |
| Market Status | Prescription |
| Company | Sun Pharma Global |
| 4 of 4 | |
|---|---|
| Drug Name | Nexium |
| PubMed Health | Esomeprazole |
| Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
| Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
| Active Ingredient | Esomeprazole magnesium |
| Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
| Route | Oral |
| Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
| Market Status | Prescription |
| Company | Astrazeneca |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
API SUPPLIERS
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Certificate Number : CEP 2020-372 - Rev 02
Issue Date : 2024-06-20
Type : Chemical
Substance Number : 1032
Status : Valid
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
Jai Radhe Sales is your partner for all your sourcing needs.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29981
Submission : 2016-11-28
Status : Active
Type : II
Date of Issue : 2022-08-12
Valid Till : 2025-07-06
Written Confirmation Number : WC-0378
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33402
Submission : 2018-12-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20169
Submission : 2007-01-17
Status : Inactive
Type : II
Certificate Number : R1-CEP 2007-276 - Rev 02
Issue Date : 2014-07-28
Type : Chemical
Substance Number : 1032
Status : Valid
Date of Issue : 2022-06-20
Valid Till : 2025-08-08
Written Confirmation Number : WC-0113
Address of the Firm :
Certificate Number : R0-CEP 2019-214 - Rev 01
Issue Date : 2022-09-28
Type : Chemical
Substance Number : 1032
Status : Valid
Certificate Number : CEP 2013-322 - Rev 03
Issue Date : 2024-09-10
Type : Chemical
Substance Number : 1032
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Omeprazole Sodium (for manufacturing only)
Registration Number : 221MF10170
Registrant's Address : Torre Esteve, Pg. de la Zona Franca, 109, 4th floor, 08038 Barcelona - Spain
Initial Date of Registration : 2009-07-30
Latest Date of Registration : 2011-10-14
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
35
PharmaCompass offers a list of Omeprazole Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Omeprazole Sodium manufacturer or Omeprazole Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Omeprazole Sodium manufacturer or Omeprazole Sodium supplier.
PharmaCompass also assists you with knowing the Omeprazole Sodium API Price utilized in the formulation of products. Omeprazole Sodium API Price is not always fixed or binding as the Omeprazole Sodium Price is obtained through a variety of data sources. The Omeprazole Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Omeprazole Sodium Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omeprazole Sodium Hydrate, including repackagers and relabelers. The FDA regulates Omeprazole Sodium Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omeprazole Sodium Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Omeprazole Sodium Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Omeprazole Sodium Hydrate supplier is an individual or a company that provides Omeprazole Sodium Hydrate active pharmaceutical ingredient (API) or Omeprazole Sodium Hydrate finished formulations upon request. The Omeprazole Sodium Hydrate suppliers may include Omeprazole Sodium Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Omeprazole Sodium Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Omeprazole Sodium Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Omeprazole Sodium Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Omeprazole Sodium Hydrate DMFs exist exist since differing nations have different regulations, such as Omeprazole Sodium Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Omeprazole Sodium Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Omeprazole Sodium Hydrate USDMF includes data on Omeprazole Sodium Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Omeprazole Sodium Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Omeprazole Sodium Hydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Omeprazole Sodium Hydrate Drug Master File in Japan (Omeprazole Sodium Hydrate JDMF) empowers Omeprazole Sodium Hydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Omeprazole Sodium Hydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Omeprazole Sodium Hydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Omeprazole Sodium Hydrate suppliers with JDMF on PharmaCompass.
A Omeprazole Sodium Hydrate CEP of the European Pharmacopoeia monograph is often referred to as a Omeprazole Sodium Hydrate Certificate of Suitability (COS). The purpose of a Omeprazole Sodium Hydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Omeprazole Sodium Hydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Omeprazole Sodium Hydrate to their clients by showing that a Omeprazole Sodium Hydrate CEP has been issued for it. The manufacturer submits a Omeprazole Sodium Hydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Omeprazole Sodium Hydrate CEP holder for the record. Additionally, the data presented in the Omeprazole Sodium Hydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Omeprazole Sodium Hydrate DMF.
A Omeprazole Sodium Hydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Omeprazole Sodium Hydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Omeprazole Sodium Hydrate suppliers with CEP (COS) on PharmaCompass.
A Omeprazole Sodium Hydrate written confirmation (Omeprazole Sodium Hydrate WC) is an official document issued by a regulatory agency to a Omeprazole Sodium Hydrate manufacturer, verifying that the manufacturing facility of a Omeprazole Sodium Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Omeprazole Sodium Hydrate APIs or Omeprazole Sodium Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Omeprazole Sodium Hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Omeprazole Sodium Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
Omeprazole Sodium Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Omeprazole Sodium Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Omeprazole Sodium Hydrate GMP manufacturer or Omeprazole Sodium Hydrate GMP API supplier for your needs.
A Omeprazole Sodium Hydrate CoA (Certificate of Analysis) is a formal document that attests to Omeprazole Sodium Hydrate's compliance with Omeprazole Sodium Hydrate specifications and serves as a tool for batch-level quality control.
Omeprazole Sodium Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Omeprazole Sodium Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Omeprazole Sodium Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Omeprazole Sodium Hydrate EP), Omeprazole Sodium Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Omeprazole Sodium Hydrate USP).
